New plasma biomarker to detect Alzheimer’s disease in Down syndrome individuals

Down Alzheimer - Plasma Markers - APOE

Plasma biomarkers Scientists worldwide are immersed in the race for accurate, non-invasive and accessible biomarkers to detect and diagnose Alzheimer’s Disease. To date, major scientific advances allowed the identification of several biomarkers in cerebrospinal fluid or using positron emission tomography (PET). Yet, these methods are either invasive or expensive and not easily accessible to all … Read more

Blood biomarkers are useful to detect Alzheimer’s disease

Marcadores Sangre - Alcolea - JNNP - Sant Pau Memory Unit

Blood biomarkers for Alzheimer’s disease Recent developments in blood markers have made possible to track the different pathophysiological processes that occur in Alzheimer’s disease through plasma analysis. Our study “Use of plasma biomarkers for AT (N) classification of neurodegenerative dementias” evaluates three of these markers and has recently been published in the Journal of Neurology, … Read more

What is the value of brain atrophy in frontotemporal dementia?

Atrophy - Illán-Gala - FTD - Sant Pau Memory Unit Barcelona

Atrophy and frontotemporal dementia The behavioral variant of frontotemporal dementia is a frequent cause of neurodegenerative dementia and the first cause of Frontotemporal Lobular Degeneration. Patients with the behavioral variant of frontotemporal dementia present a progressive personality change that begins years before diagnosis and can be confused with other neurodegenerative and psychiatric diseases. Identifying atrophy … Read more

Overlapping microstructural changes in the brain of patients with ALS and frontotemporal dementia

ELA - DFT microestructura - Sant Pau Memory Unit - Barcelona

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) Until a few years ago, amyotrophic lateral sclerosis or ALS was considered a neurodegenerative disease that caused a progressive loss of strength with preservation of intellectual functions. However, in recent years we have learned that patients with ALS can frequently present with cognitive and personality changes that … Read more

NPTX2: a new biomarker of neuronal dysfunction in adults with Down syndrome

NPTX2 - Down - Belbin - Sant Pau Memory Unit

Alzheimer’s disease is the major cause of death in adults with Down syndrome. Thus, there is an urgent need for objective biomarkers that can improve early diagnosis and monitor progression of Alzheimer’s disease in the Down syndrome population. Our recent study, entitled “Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer’s disease-related inhibitory circuit dysfunction … Read more

Estrella Morenas defends her Doctoral Thesis

Morenas - Doctoral - Lewy

Estrella Morenas has defended today her Doctoral Thesis entitled “Multimodal biomarkers studies in the continuum Dementia with Lewy bodies – Alzheimer’s disease“. The academical act of defense of her doctoral thesis has taken place at the Hospital de Sant Pau. This work, directed by Dr. Alberto Lleó and Dr. Juan Fortea, deepens into clinical aspects … Read more